Effective Exon Skipping and Dystrophin Restoration by 2′-O-Methoxyethyl Antisense Oligonucleotide in Dystrophin-Deficient Mice

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Yang, Lu ^a   Niu, Hongjing ^a   Gao, Xianjun ^a   Wang, Qingsong ^a   Han, Gang ^a   Cao, Limin ^a   Cai, Chunquan ^a   Weiler, Jan ^b   Yin, Haifang ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2' O METHYL PHOSPHOROTHIOATE ANTISENSE OLIGONUCLEOTIDE; 25 MER METHOXYETHYL PHOSPHOROTHIOATE ANTISENSE OLIGONUCLEOTIDE; 29 O METHOXYETHYL ANTISENSE OLIGONUCLEOTIDE; ANTISENSE OLIGONUCLEOTIDE; DYSTROPHIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DUCHENNE MUSCULAR DYSTROPHY; EXON; EXON SKIPPING; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MYOBLAST; MYOTUBE; NONHUMAN; PROTEIN DEFICIENCY; TIBIALIS ANTERIOR MUSCLE;

ANIMALS; DISEASE MODELS, ANIMAL; DYSTROPHIN; EXONS; GENETIC THERAPY; HUMANS; INJECTIONS, INTRAMUSCULAR; MICE; MICE, TRANSGENIC; MUSCLE FIBERS, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; MYOBLASTS; OLIGONUCLEOTIDES, ANTISENSE;

MUS;

EID: 84876832935     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061584     Document Type: Article

References (37)

1. Wood MJ, Gait MJ, Yin H, (2010) RNA-targeted splice-correction therapy for neuromuscular disease. Brain 133(Pt4): 957-972.
2. Mountoni F, Wood MJ, (2011) Targeting RNA to treat neuromuscular disease. Nat Rev 10: 621-637.
3. Aartsma-Rus A, Janson AA, Kaman WE, Bremmer-Bout M, den Dunnen JT, et al. (2003) Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients. Hum Mol Genet 12: 907-914.
4. Arechavala-Gomeza V, Graham IR, Popplewell LJ, Adams AM, Aartsma-Rus A, et al. (2007) Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle. Hum Gene Ther 18: 798-810.
5. Lu QL, Mann CJ, Lou F, Bou-Gharios G, Morris GE, et al. (2003) Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nat Med 9: 1009-1014.
6. Cirak S, Arechavala-Gomeza V, Guglieri M, Feng L, Torelli S, et al. (2011) Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 378: 595-605.
7. Goemans NM, Tulinius M, van den Akker JT, Burm BE, Ekhart PF, et al. (2011) Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med 364: 1513-1522.
8. Kinali M, Arechavala-Gomeza V, Feng L, Cirak S, Hunt D, et al. (2009) Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol 8: 918-928.
9. Van Deutekom JC, Janson AA, Ginjaar IB, Frankhuizen WS, Aartsma-Rus A, et al. (2007) Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 357: 2677-2686.
10. Heemskerk H, de Winter CL, van Ommen GJ, van Deutekom JC, Aartsma-Rus A, (2009) Development of antisense-mediated exon skipping as a treatment for duchenne muscular dystrophy. Ann N Y Acad Sci 1175: 71-79.
11. Mann CJ, Honeyman K, Cheng AJ, Ly T, Lloyd F, et al. (2001) Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. Proc Natl Acad Sci U S A 98: 42-47.
12. Van Deutekom JC, Bremmer-Bout M, Janson AA, Ginjaar IB, Baas F, et al. (2001) Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells. Hum Mol Genet 10: 1547-1554.
13. Wilton SD, Lloyd F, Carville K, Fletcher S, Honeyman K, et al. (1999) Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides. Neuromuscul Disord 9: 330-338.
14. Yin H, Betts C, Saleh AF, Ivanova GD, Lee H, et al. (2010) Optimization of peptide nucleic acid antisense oligonucleotides for local and systemic dystrophin splice correction in the mdx mouse. Mol Ther 18: 819-827.
15. Yin H, Lu Q, Wood M, (2008) Effective exon skipping and restoration of dystrophin expression by peptide nucleic acid antisense oligonucleotides in mdx mice. Mol Ther 16: 38-45.
16. Yin H, Moulton HM, Betts C, Seow Y, Boutilier J, et al. (2009) A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice. Hum Mol Genet 18: 4405-4414.
17. Yin H, Moulton HM, Seow Y, Boyd C, Boutilier J, et al. (2008) Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function. Hum Mol Genet 17: 3909-3918.
18. Moulton HM, (2012) Cell-penetrating peptides enhance systemic delivery of antisense morpholino oligomers. Methods Mol Biol 867: 407-414.
19. Manoharan M, (1999) 2′-carbohydrate modifications in antisense oligonucleotide therapy: importance of conformation, configuration and conjugation. Biochim Biophys Acta 1489: 117-130.
20. Chi KN, Eisenhauer E, Fazli L, Jones EC, Goldenberg SL, et al. (2005) A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst 97: 1287-1296.
21. Geary RS, Watanabe TA, Truong L, Freier S, Lesnik EA, et al. (2001) Pharmacokinetic properties of 2′-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats. J Pharmacol Exp Ther 296: 890-897.
22. Geary RS, Yu RZ, Watanabe T, Henry SP, Hardee GE, et al. (2003) Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2′-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species. Drug Metab Dispos 31: 1419-1428.
23. Kastelein JJ, Wedel MK, Baker BF, Su J, Bradley JD, et al. (2006) Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation. 114: 1729-1735.
24. Yu RZ, Kim TW, Hong A, Watanabe TA, Gaus HJ, et al. (2007) Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100. Drug Metab Dispos 35: 460-468.
25. Yu RZ, Zhang H, Geary RS, Graham M, Masarjian L, et al. (2001) Pharmacokinetics and pharmacodynamics of an antisense phosphorothioate oligonucleotide targeting Fas mRNA in mice. J Pharmacol Exp Ther 296: 388-395.
26. El-Andaloussi S, Johansson HJ, Holm T, Langel U, (2007) A novel cell-penetrating peptide, M918, for efficient delivery of proteins and peptide nucleic acids. Mol Ther 15: 1820-1826.
27. Wang Q, Yin H, Camelliti P, Betts C, Moulton H, et al. (2010) In vitro evaluation of novel antisense oligonucleotides is predictive of in vivo exon skipping activity for Duchenne muscular dystrophy. J Gene Med 12: 354-364.
28. Hua Y, Sahashi K, Hung G, Rigo F, Passini MA, et al. (2010) Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev 24(15): 1634-1644.
29. Sazani P, Gemignani F, Kang S, Maier MA, Manoharan M, et al. (2002) Systemically delivered antisense oligomers upregulate gene expression in mouse tissues. Nat Biotech 20: 1228-1233.
30. Natt F, Martin P, Preparation of phosphorothioate-containing DNA using aminodithiazolthiones as sulfuration reagents. Patents: EP 991-19768, US 981-68447, CAN 132:279477, AN 2000: 240734.
31. Morgan JE, Beauchamp JR, Pagel CN, Peckham M, Ataliotis P, et al. (1994) Myogenic cell lines derived from transgenic mice carrying a thermolabile T antigen: a model system for the derivation of tissue-specific and mutation-specific cell lines. Dev Biol 162(2): 486-498.
32. Heemskerk HA, de Winter CL, de Kimpe SJ, van Kuik-Romeijn P, Heuvelmans N, et al. (2009) In vivo comparison of 2′-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping. J Gene Med 11: 257-266.
33. Akdim F, Stroes ES, Sijbrands EJ, Tribble DL, Trip MD, et al. (2010) Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy. J Am Coll Cardiol 55: 1611-1618.
34. Chia S, Dent S, Ellard S, Ellis PM, Vandenberg T, et al. (2009) Phase II trial of OGX-011 in combination with docetaxel in metastatic breast cancer. Clin Cancer Res 15: 708-713.
35. Laskin JJ, Nicholas G, Lee C, Gitlitz B, Vincent M, et al. (2012) Phase I/II trial of custirsen (OGX-011), an inhibitor of clusterin, in combination with a gemcitabine and platinum regimen in patients with previously untreated advanced non-small cell lung cancer. J Thorac Oncol 7: 579-586.
36. Saad F, Hotte S, North S, Eigl B, Chi K, et al. (2011) Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c. Clin Cancer Res 17: 5765-5773.
37. Sewell KL, Geary RS, Baker BF, Glover JM, Mant TG, et al. (2002) Phase I trial of ISIS 104838, a 2′-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha. J Pharmacol Exp Ther 303: 1334-1343.